Fidelity Investments’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Fidelity Investments’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,555,678	Closed	-$920K	–	4496
2019 Q3	$920K	Sell	4,555,678 -25,618	-0.6%	-$17.3K	﹤0.01%	2436
2019 Q2	$3.99M	Buy	4,581,296 +91,606	+2%	+$143K	﹤0.01%	2160
2019 Q1	$10.4M	Buy	4,489,690 +1,318,675	+42%	+$3.57M	﹤0.01%	1852
2018 Q4	$7.36M	Buy	3,171,015 +51,046	+2%	+$450K	﹤0.01%	1905
2018 Q3	$46.2M	Buy	3,119,969 +10,109	+0.3%	+$161K	0.01%	1309
2018 Q2	$47.2M	Sell	3,109,860 -102	-0%	-$1.73K	0.01%	1302
2018 Q1	$58.4M	Buy	3,109,962 +29,127	+0.9%	+$509K	0.01%	1223
2017 Q4	$55M	Buy	3,080,835 +1,151	+0%	+$24.3K	0.01%	1249
2017 Q3	$66.3M	Buy	+3,079,684	New	+$67.6M	0.01%	1170

Other funds holding SNNA

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Private Ocean San Rafael, California $1.13B AUM 11.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Fidelity Investments's SNNA Position: Q4 2019 in Review

Fidelity Investments sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2019, closing a stake of 4,555,678 shares — an estimated $920K sold.

Fidelity Investments first reported a position in SNNA in Q3 2017 and held it in 9 quarters. The position peaked at $66.3M in Q3 2017. 4 funds tracked by Wall St. Rank hold SNNA as of Q4 2019.

Fidelity Investments reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Fidelity Investments sold 4,555,678 Sienna Biopharmaceuticals, Inc. shares in Q4 2019, an estimated $920K.
Fidelity Investments first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 9 quarters.
Fidelity Investments's Sienna Biopharmaceuticals, Inc. position peaked at $66.3M in Q3 2017.
4 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2019.

Based on Fidelity Investments's 13F filing for Q4 2019, filed 7 Feb 2020.